Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B

Clinical Transplantation

Volumn 24, Issue 2, 2010, Pages 207-212

  Tse, Kai Chung ^a   Yap, Desmond Y H ^a   Tang, Colin S O ^a   Yung, Susan ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatitis B; Lamivudine resistance; Renal allograft recipient

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; CREATININE; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HUMAN; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CREATININE; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; VIRAL LOAD;

EID: 77952905778     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01090.x     Document Type: Article

References (29)

1. Bang BK, Yang CW, Yoon SA. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients. Nephron 1995, 70:397.
2. Mathurin P, Mouquet C, Poynard T. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999, 29:257.
3. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JC. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001, 21:300.
4. Chan TM, Wu PC, Li FK, Lai CL, Cheng IKP, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998, 115:177.
5. Durlik M, Lewandowska D. Lamivudine therapy for chronic hepatitis B in renal transplant recipients. Eur J Gastroenterol Hepatol 2004, 16:1261.
6. Chan TM, Fang GX, Tang CSO, Cheng IKP, Lai KN, Ho SKN. Pre-emptive lamuvidine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002, 36:1246.
7. Chayama K, Suzuki Y, Kobayashi M. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takover by wild type after cessation of therapy. Hepatology 1998, 27:1711.
8. Hunt C, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000, 31:1037.
9. Hussain M, Lok ASF. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepatol 1999, 6:183.
10. Chan TM, Tse KC, Tang CSO, Lai KN, Ho SKN. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004, 4:1103.
11. Sherman M, Yurdaydin C, Sollano J. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039.
12. Perrillo R, Hann HW, Mutimer D. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004, 126:81.
13. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005, 45:804.
14. Stuyver LJ, Locarnini SA, Lok A. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33:751.
15. Ho SKN, Yam WC, Leung ETK. Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes. J Med Microbiol 2003, 52:397.
16. Zar JH. Comparing simple linear regression equations. Biostatistical Analysis 1999, 360. Zar JHRyu YSnavely SL. In, eds, NJ, Prentice Hall
17. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models 1996, Clark, NC, SAS Institute
18. Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001, 4:118.
19. Yuen MF, Yuan HJ, Sablon E. Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol 2004, 42:3932.
20. Chan HL, Chui AK, Lau WY. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 2004, 18:295.
21. Seehofer D, Rayes N, Steinmuller T. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001, 7:976.
22. Liu CJ, Kao JH, Chen PJ. Overlap of lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. J Viral Hepat 2006, 13:387.
23. Kim KM, Choi WB, Lim YS. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci 2005, 20:821.
24. Peters MG, Hann Hw H, Martin P. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91.
25. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutatn using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005, 11:807.
26. Garcia A, Mazuecos A, Gonzalez P. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. Transplant Proc 2005, 37:1462.
27. de Silva HJ, Dassanayake AS, Manamperi A, de Silva AP. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc 2006, 38:3118.
28. Fontaine H, Vallet-Pichard A, Chaix ML. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005, 80:1086.
29. Dai CY, Chuang WL, Hsieh MY. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res 2007, 75:146.